These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15793936)

  • 1. The RESIST trials--superiority of tipranavir over other PIs.
    Gonzalez-Lahoz J
    AIDS Rev; 2004; 6(4):244-5. PubMed ID: 15793936
    [No Abstract]   [Full Text] [Related]  

  • 2. [Perspectives: hope for therapy experienced patients. Tipranavir shows superior effectiveness with comparable safety].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():44-5. PubMed ID: 16385873
    [No Abstract]   [Full Text] [Related]  

  • 3. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA notifications. Accelerated approval of tipranavir.
    AIDS Alert; 2005 Nov; 20(11):131. PubMed ID: 16363051
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA approves Aptivus (tipranavir).
    Pham PA
    Hopkins HIV Rep; 2005 Jul; 17(4):6-7. PubMed ID: 16419308
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-HIV agents. Tipranavir for treatment-experienced PHAs.
    TreatmentUpdate; 2007 Jan; 19(1):8. PubMed ID: 17390481
    [No Abstract]   [Full Text] [Related]  

  • 7. Tipranavir.
    Gallant J
    Drugs; 2003; 63(15):1619-20. PubMed ID: 12887269
    [No Abstract]   [Full Text] [Related]  

  • 8. Tipranavir reduces viral load.
    AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412583
    [No Abstract]   [Full Text] [Related]  

  • 9. Tipranavir gets approved.
    AIDS Patient Care STDS; 2005 Sep; 19(9):615-6. PubMed ID: 16245408
    [No Abstract]   [Full Text] [Related]  

  • 10. New hope in tipranavir. New Boehringer-Ingelheim protease inhibitor may succeed where others fall short.
    Rodriguez E
    Posit Living; 2001; 10(6):15. PubMed ID: 11702749
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.
    Walmsley SL; Cotte L; Rusconi S; Ward DJ; Hicks CB; Meier U; Valdez H; Boucher CA
    AIDS; 2007 Oct; 21(16):2245-8. PubMed ID: 18090054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipranavir in the protease inhibitors arena.
    Vergani B; Rusconi S
    Drugs R D; 2011 Dec; 11(4):291-3. PubMed ID: 22133386
    [No Abstract]   [Full Text] [Related]  

  • 13. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
    TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA approval: tipranavir.
    Sax PE
    AIDS Clin Care; 2005 Aug; 17(8):78. PubMed ID: 16193574
    [No Abstract]   [Full Text] [Related]  

  • 16. Tipranavir: the first nonpeptidic protease inhibitor.
    Cheonis N
    BETA; 2004; 16(2):15-7. PubMed ID: 15104065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.
    Raffi F; Battegay M; Rusconi S; Opravil M; Blick G; Steigbigel RT; Kraft M; Neubacher D; Sabo JP
    AIDS; 2007 Sep; 21(14):1977-80. PubMed ID: 17721109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV agents. Unexpected results from a tipranavir study.
    TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836
    [No Abstract]   [Full Text] [Related]  

  • 19. 48-week RESIST data confirms TPV benefit.
    Gadd C
    IAPAC Mon; 2006 Jan; 12(1):9. PubMed ID: 17249129
    [No Abstract]   [Full Text] [Related]  

  • 20. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
    Hill A; Moyle G
    HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.